The Company is incorporated in Stockholm, Sweden
Calliditas was first listed at Nasdaq Stockholm in 2018, and at Nasdaq US in 2020
Calliditas is listed on the NASDAQ Global Select Market under the ticker symbol CALT and on NASDAQ Stockholm under the ticker symbol CALTX.
Calliditas’ fiscal year end is December 31
Marie Galay, IR Manager
Telephone: +44 79 55 12 98 45
The product is also approved in the European Union under the brand name Kinpeygo.
Calliditas partnered with Everest Medicines to commercialise NEFECON® in Greater China and Singapore in 2019. In July 2021, Calliditas announced a partnership with STADA to commercialise NEFECON in the European Economic Area (EEA) member states, Switzerland and the UK.
The NefIgArd trial is still ongoing, with the full data readout expected in early 2023. Calliditas is also conducting an open label extension trial with NEFECON®.
With its drug candidate setanaxib, a first-in-class NOX1/4 Inhibitor, Calliditas has initiated a Phase 2b/3 adaptive design trial in PBC and a Phase 2 study in head and neck cancer. The studies can be found on clinicaltrials.gov under the identifiers NCT05014672 and NCT05323656, respectively. For more info about the TRANSFORM trial in PBC, you can also visit our study website here: https://en-us.transform-study.com/